SQA-VISION VALIDATION REPORT
|
|
- Asher Bishop
- 5 years ago
- Views:
Transcription
1 Objective SQA-VISION VALIDATION REPORT T test the new cnvenience features f the SQA-Visin vs. the SQA-V and manual semen assessment: Swim-up Density Gradient Lngevity Vitality Mrphlgy Cunter Scanning Debris/Rund Cells SQA-Visin Visualizatin Validatin These parameters were always available t the SQA-V custmers, but were tracked r recrded manually n separate pages r frms. The new SQA-Visin system is based n the SQA-V platfrm (1), but streamlines the assessment and data cllectin prcesses by allwing this infrmatin t be part f the standard patient recrd. The bjective f this trial is t determine that these semen assessment features perfrm as designed, and prvide the crrect results vs. reference methd (SQA-V and manual semen assessment where applicable) and vs. manufacturer claims. Nne f these cnvenience features include new algrithms fr reprting semen values. Additinally, sme f the features are nt run autmatically n the SQA-Visin, but are run manually using the visualizatin system f the SQA-Visin instead f the micrscpe. In these cases, the micrscpe will be cnsidered the GOLD STANDARD fr cmparisn. Study Design Tw clinical trials were cnducted: at MES Ltd., Israel (169 semen samples f the dnrs), at the University Hspital f Nantes, France (57 semen samples frm patients being evaluated at the andrlgy unit). In ttal, 226 human semen samples were tested. Types f semen samples/tests run: Fresh, Washed, Swim-up, Density Gradient, Lngevity, Vitality, Mrphlgy using the SQA-Visin cunter, samples with Debris/Rund Cells, Visualizatin cmpartment validatin. All semen samples were cllected, split int tw aliquts and run accrding t WHO 5 th editin manual (2) standards and per the manufacturer s prtcl fr cmparisn: Split int tw aliquts each hmgeneusly mixed semen sample after cmplete liquefactin If samples d nt liquefy cmpletely r are highly viscus, treat with chymtrypsin (QwikCheck Liquefactin Kit) and nly then split int tw aliquts Perfrm all testing at rm temperature (RT) Mtility and Prgressive Mtility Assessment: Assess ne aliqut first under the micrscpe in duplicate as defined by WHO 5 th editin manual, within 1 hur f cllectin (and directly fllwing sample liquefactin) and in parallel test the secnd aliqut n the SQA-Visin. Manual cncentratin : Assess using an Imprved Neubauer chamber fllwing WHO 5 th table fr cmparing duplicate cunts Cunt a minimum f 200 cells, twice as required by the WHO 5 th editin manual Use a minimum f 100 µl f raw semen fr any dilutins in rder t avid dilutin errrs Use psitive displacement calibrated lab pipettes File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 1 f 17
2 Manual mrphlgy: Prepare Papaniclau stained smears and assess them based n WHO 5 th guidelines fr nrmal/abnrmal mrphlgy SQA-V: Run the samples per SQA-V nscreen instructins fllwing the present prtcl guidelines (fr each sample, run in duplicate using the same capillary) Save results by clicking Imprt Test in the V-Sperm SQA-Visin: Run the samples per SQA-Visin nscreen instructins fllwing the present prtcl guidelines (fr each sample, run in duplicate using the same capillary) SQA-Visin Visualizatin: The SQA-Visin Visualizatin was validated vs. the micrscpe (Neubauer chamber) and vs. SQA-V Visualizatin as fllws: Run the same varying cncentratins f 20 sperm samples and 8 latex beads samples f varying cncentratins n the SQA-Visin Visualizatin screen (manual mde) Run the same samples using the Imprved Neubauer cunting chamber and additinally n the SQA-V Visualizatin and cmpare results. Materials and Methds Equipment and materials SQA-Visin system SQA-V System + V-Sperm Imprved Neubauer chamber Phase cntrast micrscpe Centrifuge with 15 ml tubes fr centrifugatin Freezing vials Egg Ylk Freezing media Pasteur pipettes Standard lab slides and cver slips 22 X 22 mm Fixed cverslip slides SQA-V capillaries CellVu pre-stained mrphlgy slides Papaniclau reagents Esin reagent fr Vitality test (see recipe belw) Optiprep density gradient medium 2.77% and 1.56% NaCl Fresh, Washed, Swim-up, Density Gradient and Lngevity semen samples Lab pipettes + tips, calculatrs, cunters, data cllectin sheets 10 ml cups with caps Glves, Kimwipes QwikCheck Beads, Test Strips, Liquefactin and Dilutin kits SQA-Visin default settings Cncentratin standard: Neubauer Testing criteria: WHO 5 th File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 2 f 17
3 Autmated pening f vide screen fr debris/rund cells scanning: Cncentratin < 15M/ml OR Mtility < 40% Lngevity: 3 tests - initial test is run at 0 pint, then tw mre tests in 2h intervals; all three recrds are shwn in ne reprt Manual Mrphlgy set t Nrmal/Abnrmal Vitality: Yes QC: QwikCheck beads accrding t the kit labeling (Run 3 levels f QwikCheck beads cntrl daily befre testing samples). Sample inclusin/exclusin criteria Highly viscus r incmpletely liquefied semen samples treated with the QwikCheck Liquefactin kit are included in the trial Semen samples with vlume < 1 ml are excluded frm the trial Samples with methdlgical issues are excluded frm the trial (6 samples) Sample cllectin and preparatin Fresh Samples: Cllect Fresh samples accrding t WHO 5 th manual prcedure Liquefy fr up t 1 hur. If nt liquefied, treat with 1 vial f QwikCheck Liquefactin Kit (α-chymtrypsin) and test after cmplete liquefactin (within 10 minutes) Mix each sample thrughly befre prceeding Mark each sample with a unique sample #, and then split int tw aliquts: SQA-Visin and SQA-V: ml Micrscpe: remaining sample with minimum f 100µl D nt dilute the sample befre splitting it int aliquts. If diluting, fllw the manufacturer s instructins based n the methd used Run the sample in the Fresh mde f the SQA-Visin and SQA-V Washed Samples: Add 2 ml semen and up t 10 ml Earle's buffer t the centrifuge tube, mix thrughly Centrifuge at 220g fr 10 min Remve the supernatant Re-suspend the pellet with 1 ml Earle's buffer Run the sample in the Washed mde f the SQA-Visin and SQA-V Swim-up Samples: Transfer 2 ml f a Fresh semen sample int the test tube. Layer 2ml Earle's buffer n the tp (d nt mix with sample) Incline the tube t a 45 0 angle Incubate the tube fr 1 hur at 37 0 C Cllect the upper layer f Earle's buffer (~ 2 ml) Run the cllected sample in the Swim-up mde f the SQA-Visin and the lw vlume washed mde f the SQA-V File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 3 f 17
4 Density Gradient Samples: Prepare the Density Media: 40% OptiPrep: 1.35 ml f stck OptiPrep ml 2.77% NaCl 25% OptiPrep: 0.85 ml f stck OptiPrep ml 1.56% NaCl Place up t 1 ml (abut half f the semen vlume) f 40% Gradient slutin int a tube. Carefully pur up t 1 ml (abut half f semen vlume) f 25% Gradient slutin, alng the wall f the tube in rder t create tw layers. Mix the semen sample and add the semen gently alng the tube wall t create a third layer. If the semen vlume is mre than 3ml distribute the samples int tw tubes. Centrifuge at 300g (1350 rpm) fr 20 minutes. Cllect the pellet int a new tube. Re-suspend the pellet with 1 ml Earle's buffer. Run the cllected sample in the Density Gradient mde f SQA-Visin and lw vlume washed mde f the SQA-V. Lngevity Test: Fill the capillary with fresh sample, run the initial test in the SQA-Visin Lngevity mde and in the SQA-V Expel the sample frm the capillary int a 10-ml vial and incubate fr 2 hurs After incubatin, re-run the test in the SQA-Visin Lngevity mde and manually fr mtility and prgressive mtility Save results Repeat the same prcedure after 4 hurs Running Samples Parameters fr cmparisn: The SQA-Visin semi-autmated results btained by running fresh, washed and lngevity samples with mderate/high level f debris/rund cells r Cncentratin r MSC beynd autmated dynamic range (<2M/ml) vs. the micrscpe (manual): cncentratin, mtility, prgressive mtility and mrphlgy The SQA-Visin fully autmated mde (fresh, washed and lngevity samples with a lw level f debris/rund cells and Cncentratin and MSC >= 2M/ml) vs. the SQA-V: Cncentratin, mtility, prgressive mtility and mrphlgy The SQA-Visin fully autmated mde fr swim-up and density gradient samples vs. the SQA-V: Mtile Sperm Cncentratin (MSC) and Prgressively Mtile Sperm Cncentratin (PMSC) reprted by bth systems The SQA-Visin CellVu Mrphlgy t micrscpe (manual) Papaniclau (PAP) Mrphlgy The SQA-Visin Vitality t manual (micrscpe) Vitality SQA-Visin and SQA-V sample testing: Turn n the SQA-Visin and the SQA-V. Activate the Visin HOME screen and V-Sperm. Set the SQA-V and SQA-Visin default settings accrding t the setting instructins listed abve. File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 4 f 17
5 Run 3 levels f QwikCheck Beads cntrl material befre testing samples. Prepare the Mrphlgy slide in advance: CellVu pre-stained slide, 5 µl semen and 22mm x 22mm cverslip pressed by finger t make a cell mnlayer. Prepare in advance Vitality slide: Reagent Preparatin 1. NaCl, 0.9% (w/v): disslve 0.9 g f NaCl in 100 ml purified water 2. Esin Y, 0.5% (w/v): disslve 0.5 g f esin Y (clr index 45380) in 100 ml f 0.9% NaCl Prcedure 1. Mix the semen sample well 2. Remve an aliqut f 5 µl f semen and cmbine with 5 µl f esin slutin n a micrscpe slide 3. Mix with a pipette tip, swirling the sample n the slide 4. Cver with a 22 mm x 22 mm cverslip and leave at least fr 30 secnds Enter the patient/sample data. Assess the ph and WBC using QwikCheck Test Strips and enter their values where apprpriate. Fllw the nscreen instructins f each system and run the test. If the results fall belw the cut-ffs fr lw quality semen (Cncentratin r MSC <2M/ml), the SQA- Visin will pen the manual sample assessment screen autmatically. The SQA-V autmatically displays a limited reprt in this case (Cncentratin <2M/ml, etc.); Then the SQA-Visin manual results will be cmpared t the micrscpe manual data. T use the Visin Manual Assessment Screen: Fill a fixed cverslip slide with semen sample per prduct and SQA-Visin nscreen instructins. View the slide in the visualizatin cmpartment f the SQA-Visin and cunt the mtile and immtile sperm cells manually (at least 200 spermatza in ~ fields) Enter the manual data in the fields prvided and btain a reprt. Run a secnd testing cycle using the same testing capillary and sample. Run the Mrphlgy (CellVu) and Vitality (esin) tests. Insert the Mrphlgy slide int the SQA-Visin visualizatin cmpartment and assess nrmal and abnrmal spermatza using the cunter (at least 200 spermatza in apprx fields f view). Insert the Vitality slide int the SQA-Visin visualizatin cmpartment and assess using the cunter. Cunt live (nn-stained) and dead (stained) spermatza (at least 200 spermatza twice in apprx fields f view) at zm ut. In parallel, examine the slides under the micrscpe. Save the data. Manual Mtility: Assess mtility within ne hur f cllectin, immediately after full liquefactin f the sample. Run all tests in the SQA-Visin, SQA-V and the micrscpe in parallel r within 2 minutes f each ther t eliminate the effect f time difference. Assessing mtility under the micrscpe 1. Cunt each sample in duplicate 2. Mix the semen sample well File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 5 f 17
6 3. Remve an aliqut f semen immediately after mixing, allwing n time fr the spermatza t settle 4. Fr each replicate, prepare a wet preparatin apprximately 20 µm deep 5. Prepare standard slides accrding t WHO 5 th manual (p. 21): Lad 10 µl f semen nt a standard micrscpe slide and cver with 22mm X 22mm cverslip prviding 20-micrn depth 6. Wait fr the sample t stp drifting (within 60 secnds) 7. Examine the slide under phase-cntrast ptics at x200 r x400 magnificatin 8. Assess 200 spermatza per replicate t determine the percentage f different mtile categries 9. Per WHO 5 th ed. manual (p. 22), the mtility f each spermatzn is graded as fllws: Prgressive mtility (PR): spermatza mving actively, either linearly r in a large circle, regardless f speed Nn-prgressive mtility (NP): all ther patterns f mtility with an absence f prgressin, e.g., swimming in small circles, the flagella frce hardly displacing the head, r when nly a flagellar beat can be bserved Immtility (IM): n mvement 10. Cmpare the replicate values t check if they are acceptably clse per WHO 5th table 2.1. If s, average results; if nt, prepare and assess new samples 11. Recrd Mtility values f each sample in the Assessment Frm Manual Sperm Cncentratin: 1. Use the Neubauer cunting chamber fr the assessment f cncentratin fllwing the WHO 5 th table (table 2.3 belw) 2. Cunt a minimum f 200 cells twice 3. T cmpare duplicate cunt accuracy use WHO 5th table 2.4 (belw) 4. Recrd the Sperm Cncentratin values fr each sample in the Assessment Frm prvided Manual Mrphlgy: Fllw the steps utlined in the WHO 5 th manual (Sectin 2.13 Sperm mrphlgy, p. 56) recmmended fr testing mrphlgy: 1. Prepare a minimum f tw smears f fresh semen (10µl) fr duplicate measurements 2. Stain using Papaniclau methd 3. Munt the slide with a cverslip if the slide is t be kept fr a lng time Mrphlgy Cunting 1. Examine the slide under il immersin with bright field ptics at x1000 magnificatin 2. Mrphlgical evaluatin shuld be perfrmed in several systematically selected areas f the slide 3. Cunt all spermatza per WHO 5 th criteria, nting nly the # Nrmal and # Abnrmal frms (nt the differential f defects) in rder t establish the % nrmal frms. If apprpriate, cunt differential mrphlgy as well 4. Cmpare replicate values t WHO 5th table 2.1 t determine acceptability; If nt, re-read the slides 5. Recrd the Mrphlgy values f each sample in the Assessment Frm prvided File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 6 f 17
7 File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 7 f 17
8 Statistics and Acceptance Criteria Statistical analysis was perfrmed using the MedCalc and Excel prgrams: Crrelatin Sensitivity (an ability t detect abnrmal cases vs. reference methd) Specificity (an ability t detect nrmal cases vs. reference methd) Precisin: CV (cefficient f variatin) Acceptance Criteria is based n the SQA-Visin prduct perfrmance claims (applicable t any sample type/test results including Lngevity presented in the study): Crrelatin: Sperm Cncentratin: >= 0.90 Ttal Mtile (PR + NP): >= 0.80 (in Lngevity, each step is cmpared vs. reference methd as a separate test) Prgressive Mtility (PR): >= 0.80 (same as abve) MSC: >= 0.85 PMSC: >= 0.80 Vitality: >= 0.90 Sensitivity: Sperm Cncentratin: >= 90% Ttal Mtile (PR + NP): >= 85% Prgressive Mtility (PR): >= 85% Nrmal Frms: >= 80% MSC: >= 85% PMSC: >= 85% Vitality: >= 90% Specificity: Sperm Cncentratin: >= 85% Ttal Mtile (PR+NP): >= 80% Prgressive Mtility (PR): >= 80% Nrmal Frms: >= 90% MSC: >= 80% PMSC: >= 80% Vitality: >= 90% SQA-Visin cefficients f variatin (CV) fr Cncentratin, Ttal Mtile and Prgressive Mtility parameters <10% SQA-Visin Visualizatin: Crrelatin t Neubauer >=0.9 File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 8 f 17
9 Results Sperm Cncentratin The Sperm Cncentratin results frm a variety f semen sample types run n the SQA-Visin were statistically cmpared t the SQA-V and t manual micrscpe results (fr semi-autmated r the manual mde f the SQA- Visin). The results are summarized in the Table 1 belw: TP TN FP FN Table 1: SQA-Visin Sperm Cncentratin Sensitivity 1,2 Specificity 1,2 Crrelatin (r) SQA-Visin Intra-device CV MES Ltd., Israel (n = 169) University Hspital f Nantes, France (n = 57) Sperm Cncentratin reference value used fr calculatin sensitivity and specificity per WHO 5th ed. manual is 15 M/ml 2 Sensitivity = TP / (TP + FN) * 100; Specificity = TN / (TN + FP) * 100 Ntes: TP - True Psitive (crrectly classified as psitive - presence f disease) TN - True Negative (crrectly classified as negative - absence f disease) FP - False Psitive (nt crrectly classified as psitive - absence f disease) FN - False Negative (nt crrectly classified as negative - presence f disease) The crrelatin cefficients f the SQA-Visin Sperm Cncentratin t the SQA-V + manual results are high (0.98; 0.95). They exceed the acceptance criteria. This high crrelatin shws strng agreement between the methds. The tight relatinship between Sperm Cncentratin reprted by the SQA-Visin and SQA-V + manual methds is demnstrated graphically in Figure 1: Figure 1. SQA-Visin vs. SQA-V and manual Sperm Cncentratin The SQA-Visin Sperm Cncentratin Sensitivity and Specificity btained in the different trials greatly exceeds the acceptance cutff f 90% and 85% crrespndingly. The SQA-Visin als demnstrated excellent precisin fr assessing Sperm Cncentratin with lw cefficients f variatin f 4.5% and 4.1%, which meet the acceptance requirements. File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 9 f 17
10 Ttal Mtility (PR + NP) The Ttal Mtility sperm results frm a variety f semen sample types run n the SQA-Visin were statistically cmpared t the SQA-V and t manual micrscpe results (fr semi-autmated r the manual mde f the SQA- Visin). The results are summarized in the Table 2 belw: TP TN FP FN Table 2: SQA-Visin Ttal Mtility Sensitivity 1,2 Specificity 1,2 Crrelatin (r) SQA-Visin Intra-device CV MES Ltd., Israel (n = 178) University Hspital f Nantes, France (n = 54) Ttal Mtility reference value used fr calculatin sensitivity and specificity per WHO 5th ed. manual is 40% 2 Sensitivity = TP / (TP + FN) * 100; Specificity = TN / (TN + FP) * 100 Ntes: TP - True Psitive (crrectly classified as psitive - presence f disease) TN - True Negative (crrectly classified as negative - absence f disease) FP - False Psitive (nt crrectly classified as psitive - absence f disease) FN - False Negative (nt crrectly classified as negative - presence f disease) The crrelatin cefficients f the SQA-Visin Ttal Mtility t the SQA-V + manual results are high (0.92; 0.85) and these results equal r exceed the acceptance criteria. This high crrelatin shws strng agreement between the methds. This tight relatinship between Ttal Mtility reprted by the SQA-Visin and the SQA-V + manual methds is demnstrated graphically in Figure 2: Figure 2. SQA-Visin vs. SQA-V and manual Ttal Mtility The SQA-Visin Ttal Mtility Sensitivity and Specificity are high and exceed the acceptance cutff. The SQA- Visin als demnstrated excellent precisin when measuring Ttal Mtile sperm demnstrated by lw cefficients f variatin f (6.2%; 5.0%) which meet the acceptance requirements. File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 10 f 17
11 Prgressive Mtility (PR) The Prgressive Mtility results frm a variety f semen sample types run n the SQA-Visin were statistically cmpared t the SQA-V and t manual micrscpe results (fr semi-autmated r manual mde f the SQA- Visin). The results are summarized in the Table 3: TP TN FP FN Table 3: SQA-Visin Prgressive Mtility Sensitivity 1,2 Specificity 1,2 Crrelatin (r) SQA-Visin Intra-device CV MES Ltd., Israel (n = 161) University Hspital f Nantes, France (n = 36) Prgressive Mtility reference value used fr calculatin sensitivity and specificity per WHO 5th ed. manual is 32% 2 Sensitivity = TP / (TP + FN) * 100; Specificity = TN / (TN + FP) * 100 Ntes: TP - True Psitive (crrectly classified as psitive - presence f disease) TN - True Negative (crrectly classified as negative - absence f disease) FP - False Psitive (nt crrectly classified as psitive - absence f disease) FN - False Negative (nt crrectly classified as negative - presence f disease) The crrelatin cefficients f the SQA-Visin Prgressive Mtility results vs. the SQA-V + manual results are high (0.91; 0.85) and are equal t r exceed the acceptance criteria. This high crrelatin shws strng agreement between the methds. This tight relatinship between Prgressive Mtility reprted by the SQA-Visin and the SQA-V + manual methd is demnstrated graphically in Figure 3: Figure 3. SQA-Visin vs. SQA-V and manual Prgressive Mtility The SQA-Visin Prgressive Mtility Sensitivity and Specificity are high and exceed the acceptance cutff. The data shws that nly a few samples were categrized differently between the tw systems. This can be due t the subjectivity f the manual Prgressive Mtility assessment. The SQA-Visin als demnstrated excellent precisin fr assessing Prgressively Mtile sperm as demnstrated by lw cefficients f variatin which meet the acceptance requirements. File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 11 f 17
12 Samples with Debris and/r Rund Cells An ejaculate cntains cells ther than spermatza, sme f which may be clinically relevant. These include epithelial cells frm the geniturinary tract, as well as leukcytes and immature germ cells, the latter tw cllectively referred t as rund cells (3). Besides these elements, the ejaculate may cntain debris (particles f brken cells). These inclusins are interfering factrs fr bth manual and autmated semen assessment (2). The results f running semen samples cntaining debris and/r rund cells n the SQA-Visin as cmpared t running these same samples manually under the micrscpe are summarized in Table 4 belw. Table 4: SQA-Visin Samples with Debris and /r Rund Cells Semen Parameters TP TN FP FN Sensitivity 1,2 Specificity 1,2 Sperm Cncentratin (x10 6 /ml) n = 38 Ttal Mtile PR + NP n = 38 Prgressive PR n = 36 MES Ltd., Israel SQA-Visin Intradevice CV University Hspital f Nantes, France Sperm Cncentratin (x10 6 /ml) n = 17 Ttal Mtile PR + NP n = Prgressive PR n = The reference values fr semen parameters used fr calculatin sensitivity and specificity were per WHO 5th ed. manual 2 Sensitivity = TP / (TP + FN) * 100; Specificity = TN / (TN + FP) * 100 Ntes: TP - True Psitive (crrectly classified as psitive - presence f disease) TN - True Negative (crrectly classified as negative - absence f disease) FP - False Psitive (nt crrectly classified as psitive - absence f disease) FN - False Negative (nt crrectly classified as negative - presence f disease) The results demnstrate that the SQA-Visin Sensitivity and Specificity fr Sperm Cncentratin, Ttal Mtility and Prgressive Mtility are very high which equals r exceeds the acceptance criteria. The SQA-Visin als demnstrated very gd precisin as shwn by cefficients f variatin varying frm 3.1% t 8.5%, which meet the pass criteria. Swim-up and Density Gradient Samples Swim-up and Density Gradient prcedures are used when spermatza need t be separated frm the seminal plasma. The separatin f human spermatza frm the seminal plasma t yield a final preparatin cntaining a high percentage f mrphlgically nrmal and mtile cells, free frm debris, nn-germ cells and dead spermatza, is imprtant fr clinical practice (2). The chice f sperm preparatin technique is dictated by the nature f the semen sample (4). Fr example, a direct swim-up technique is ften used when the semen samples are cnsidered t be largely nrmal, whereas in cases f severe ligzspermia, teratzspermia r asthenzspermia, density gradients are usually preferred File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 12 f 17
13 because f the greater ttal number f mtile spermatza recvered. Density-gradients can als be altered t ptimize the handling f specific prperties f individual samples (2). The Swim-up and Density Gradient mdes f the SQA-Visin and the Washed lw vlume mde f the SQA-V require a minimum f 20 µl f semen vlume (nly the frnt sectin f the testing capillary is filled). In these cases, mtility-related parameters such as Mtile and Prgressively Mtile Sperm Cncentratin (MSC and PMSC crrespndingly) are reprted. The results f running Swim-up and Density Gradient samples n the SQA-Visin cmpared t the SQA-V are summarized in Table 5: Table 5: SQA-Visin Swim-up and Density Gradient Samples Semen Parameters TP TN FP FN Sensitivity 1,2 Specificity 1,2 Crrelatin (r) SQA-Visin Intra-device CV MES Ltd., Israel MSC (x10 6 /ml) n = PMSC (x10 6 /ml) n = The MSC and PMSC reference values used fr calculatin sensitivity and specificity are 6.0 and 5.0 (x10 6 /ml) crrespndingly 2 Sensitivity = TP / (TP + FN) * 100; Specificity = TN / (TN + FP) * 100 Ntes: TP - True Psitive (crrectly classified as psitive - presence f disease) TN - True Negative (crrectly classified as negative - absence f disease) FP - False Psitive (nt crrectly classified as psitive - absence f disease) FN - False Negative (nt crrectly classified as negative - presence f disease) The MSC and PMSC Sensitivity and Specificity fr bth systems were 100%. The crrelatin cefficients f these parameters btained using the SQA-Visin system vs. SQA-V are 0.99 (bth) which exceeds the acceptance criteria. The high sensitivity, specificity and crrelatins demnstrate a very high level f agreement between the methds. This tight relatinship between the semen parameters reprted by the SQA-Visin and the SQA-V is demnstrated graphically in Figures 4 and 5 belw. Figure 4. SQA-Visin vs. SQA-V MSC Figure 5. SQA-Visin vs. SQA-V PMSC The SQA-Visin als demnstrated gd precisin when assessing MSC and PMSC as evidenced by cefficients f variatin belw 10% which meet the acceptance requirements. File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 13 f 17
14 Lngevity Lngevity testing is a requirement in many labratries. The length f time sperm are able t remain viable after ejaculatin may be f cncern in sme cases. The sperm lngevity test assesses percent Ttal Mtile and Prgressive sperm at given time intervals. The results f running lngevity tests n the SQA-Visin cmpared t the SQA-V and the manual methd (fr cmparing the semi-autmated r manual mde f the SQA-Visin) are summarized in Table 6 belw: Table 6: Lngevity Semen Parameters TP TN FP FN Sensitivity 1,2 Specificity 1,2 Crrelatin (r) MES Ltd., Israel Ttal Mtile PR + NP n = Prgressive PR n = University Hspital f Nantes, France Ttal Mtile PR + NP n = Prgressive PR n = T Reference values fr semen parameters used fr calculating sensitivity/specificity are per WHO 5th ed. manual 2 Sensitivity = TP / (TP + FN) * 100; Specificity = TN / (TN + FP) * 100 Ntes: TP - True Psitive (crrectly classified as psitive - presence f disease) TN - True Negative (crrectly classified as negative - absence f disease) FP - False Psitive (nt crrectly classified as psitive - absence f disease) FN - False Negative (nt crrectly classified as negative - presence f disease) The results demnstrate high crrelatin cefficients fr the SQA-Visin percent Ttal Mtile and Prgressive Mtility parameters t the SQA-V + manual results; varying frm 0.84 t 0.93 which exceeds the acceptance criteria. This high crrelatin shws gd agreement between the methds. The relatinship between Ttal Mtile and Prgressive Mtility parameters reprted by the SQA-Visin and SQA-V + manual methd in the Lngevity samples is demnstrated graphically in Figures 6 and 7: Fig. 6. SQA-Visin vs. SQA-V & manual Ttal Mtile Fig. 7. SQA-Visin vs. SQA-V & manual Prgressive The sensitivity f Ttal Mtile and Prgressive Mtility parameters assessed by the SQA-Visin fr Lngevity testing is high varying frm 87.5% t 100% which exceed the acceptance cutff. The specificity f these parameters fr the Lngevity tests is als high varying frm 83.3% t 100% which is greater than the acceptance criteria. File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 14 f 17
15 Vitality Sperm Vitality, as estimated by assessing the membrane integrity f the cells, may be determined rutinely n all samples, but is especially imprtant fr samples with less than abut 40% prgressively mtile spermatza. This test can prvide a check n the mtility evaluatin, since the percentage f dead cells shuld nt exceed (within sampling errr) the percentage f immtile spermatza. The percentage f viable cells nrmally exceeds that f mtile cells. The percentage f live spermatza is assessed by identifying thse with an intact cell membrane, using dye exclusin r hyptnic swelling. The principle f the dye exclusin methd is that damaged plasma membranes, such as thse fund in nn-vital (dead) cells, allw entry f membrane-impermeant stains (2). The results f assessing esin-stained semen fr Vitality using the SQA-Visin visualizatin cmpartment cmpared t the micrscpe manual methd are summarized in Table 7 belw: Table 7: Vitality (% Live) TP TN FP FN Sensitivity 1,2 Specificity 1,2 Crrelatin (r) MES Ltd., Israel (n = 49) Vitality reference value per WHO 5th ed. manual is 58%. 2 Sensitivity = TP / (TP + FN) * 100; Specificity = TN / (TN + FP) * 100 Ntes: TP - True Psitive (crrectly classified as psitive - presence f disease) TN - True Negative (crrectly classified as negative - absence f disease) FP - False Psitive (nt crrectly classified as psitive - absence f disease) FN - False Negative (nt crrectly classified as negative - presence f disease) The crrelatin cefficient f the SQA-Visin Vitality t the manual results is 0.91 which exceeds the acceptance criteria. This high crrelatin shws gd agreement between the methds. The tight relatinship between Vitality reprted by the SQA-Visin and the manual methd is demnstrated graphically in Figure 8: Figure 8. SQA-Visin vs. manual Vitality The sensitivity and specificity f the SQA-Visin t assess Vitality vs. the manual results is very high: 100% and 94.9% respectively which exceeds the acceptance cutff. File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 15 f 17
16 Mrphlgy Summarized in Table 8 belw are the results f Mrphlgically Nrmal Frms btained by: SQA-Visin autmatically The use f CellVu pre-stained slides cunted in the SQA-Visin visualizatin cmpartment Manual assessment f Papaniclau (PAP) smears Table 8: Nrmal Frms (Mrphlgy) Semen Parameters TP TN FP FN Sensitivity 1,2 Specificity 1,2 MES Ltd., Israel SQA-Visin aut vs. CellVu (n = 45) SQA-Visin CellVu vs. Manual PAP (n = 50) University Hspital f Nantes, France SQA-Visin aut vs. Manual PAP (n = 43) Nrmal Frms (Mrphlgy) reference value per WHO 5th ed. manual is 4%. 2 Sensitivity = TP / (TP + FN) * 100; Specificity = TN / (TN + FP) * 100 Ntes: TP - True Psitive (crrectly classified as psitive - presence f disease) TN - True Negative (crrectly classified as negative - absence f disease) FP - False Psitive (nt crrectly classified as psitive - absence f disease) FN - False Negative (nt crrectly classified as negative - presence f disease) The sensitivity and specificity f the SQA-Visin nrmal mrphlgy assessed autmatically vs. the SQA-Visin CellVu data is: 80.0% and 91.4% respectively, which exceed the acceptance cutff. A cmparisn f the SQA- Visin CellVu mrphlgy with the manual PAP data resulted in sensitivity and specificity f 80.0% and 92.5% crrespndingly which als exceeds the acceptance criteria. The SQA-Visin autmated percent nrmal frms cmpared t manual PAP data shwed sensitivity f 83.3% and specificity f 96.8% (bth values are higher than the acceptance criteria). Based n this data it is pssible t cnclude that all three methds are in agreement. SQA-Visin Visualizatin Screen Validatin The SQA-Visin Visualizatin Screen was validated by cunting varying cncentratins f spermatza (20 samples) and latex beads (8 samples) using: SQA-Visin Visualizatin Imprved Neubauer cunting chamber Additinally, the SQA-Visin Visualizatin was validated vs. the SQA-V vide screen by cunting 8 sperm samples and 8 samples f latex beads. The results are summarized in Table 9 belw: Parameter Table 9: SQA-Visin Visualizatin Validatin SQA-Visin Visualizatin Cunt Manual Cunt Average SD Average SD Crrelatin (r) MES Ltd., Israel Cunt vs. Neubauer (x10 6 /ml) n = Cunt vs. SQA-V visual screen (x10 6 /ml) n = It is seen that the average values btained by manually cunting sperm cells and latex beads using the SQA-Visin Visualizatin System and the Imprved Neubauer cunting chamber are similar and the standard deviatins (SD) are very clse. A similar relatinship is demnstrated when cmparing the results f cunting sperm cells and File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 16 f 17
17 latex beads using the SQA-Visin vs. SQA-V visualizatin screen. This indicates that there are n systematic discrepancies between the methds which were cmpared. The data set als demnstrates a high level f crrelatin which is shwn graphically belw: Cnclusins Based n results f the multicenter trials, the SQA-Visin demnstrated that all assessed parameters passed the acceptance criteria. A high level f crrelatin between the SQA-Visin and SQA-V autmated + manual results (used as the standard when apprpriate) demnstrated agreement between these methds. The Sensitivity and Specificity levels fr all assessed parameters were higher than the acceptance criteria. The SQA-Visin demnstrated a high level f precisin (all CVs are belw 10%). The SQA-Visin Visualizatin can be used fr manual cunting as an accessry tl. The verall cnclusin is that the SQA-Visin system successfully passed clinical validatin shwing substantial equivalence with the SQA-V system. References 1. Agarwal A., Sharma R.K. (2007). Autmatin is the key t standardized semen analysis using the autmated SQA-V sperm quality analyzer. Fertility and Sterility, 87(1): WHO labratry manual fr the examinatin and prcessing f human semen - 5th ed., Wrld Health Organizatin Jhanissn E et al. (2000). Evaluatin f rund cells in semen analysis: a cmparative study. Human Reprductin Update, 6: Canale D et al. (1994). Inter- and intra-individual variability f sperm mrphlgy after selectin with three different techniques: layering, swimup frm pellet and Percll. Jurnal f Endcrinlgical Investigatin, 17: File: SQA-VISION VALIDATION REPORT_12_NOV_14 Page 17 f 17
Protocol. Preparation Protocol for the Non-Targeted Vevo MicroMarker Contrast Agent
Prtcl Preparatin Prtcl fr the Nn-Targeted Vev MicrMarker Cntrast Agent System Cmpatibility: This guide cntains instructins and suggestins fr wrk n the Vev2100, VevLAZR, Vev 3100 systems and transducers
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationPROTOCOL 1850 Millrace Drive, Suite 3A Eugene, Oregon
PROTOCOL Cmplex II Enzyme Activity Micrplate Assay Kit 1850 Millrace Drive, Suite 3A Eugene, Oregn 97403 MS241 Rev.0 DESCRIPTION Cmplex II Enzyme Activity Micrplate Assay Kit Sufficient materials are prvided
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationACRIN 6666 Screening Breast US Follow-up Assessment Form
Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationVolume Measurement at CT
Vlume Measurement at CT Staging and Assessment f Respnse with Quantitative CT Lawrence Schwartz, MD Department f Radilgy Clumbia University Cllege f Physicians and Surgens LSCHWARTZ@COLUMBIA.EDU Recmmendatins
More informationSystem overview Installation System Description System Default Settings and Loading I-Button Tests Components/Kits /Accessories Maintenance & Cleaning
SQA-VISION TRAINING Content of Presentation System overview Installation System Description System Default Settings and Loading I-Button Tests Components/Kits /Accessories Maintenance & Cleaning SQA-Vision
More informationINFERTILITY DIAGNOSIS
INFERTILITY Infertility is the inability t cnceive after 12 mnths f unprtected intercurse. There are multiple causes f infertility and a systematic way t evaluate the cnditin. Let s lk at sme f the causes.
More informationCoaguChek Outpatient Clinic: Quality Control Test Procedure. Action
PHSA Labratries CW Site - Pint f Care Title: CWPC_INR_0130 CaguChek Outpatient Clinic Quality Cntrl Test Prcedure CaguChek Outpatient Clinic: Quality Cntrl Test Prcedure PURPOSE: This prcedure prvides
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationAP Biology Lab 12: Introduction to the Scientific Method and Animal Behavior
Name: AP Bilgy Lab 12: Intrductin t the Scientific Methd and Animal Behavir Overview In this lab yu will: -Observe an rganism and design an experiment t investigate their respnses t envirnmental variables.
More informationRecord of Revisions to Patient Tracking Spreadsheet Template
Recrd f Revisins t Patient Tracking Spreadsheet Template Belw is a recrd f revisins made by the AIMS Center t the Patient Tracking Spreadsheet Template. The purpse f this dcument is t infrm spreadsheet
More informationGetting Started. Learning Guide. with Continuous Glucose Monitoring for the MiniMed 530G with Enlite. CGM Foundations
Getting Started with Cntinuus Glucse Mnitring fr the MiniMed 530G with Enlite Learning Guide CGM Fundatins Cntinuus Glucse Mnitring Learning Guide MiniMed 530G with Enlite - Cntinuus Glucse Mnitring Settings
More informationA pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.
NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting
More informationThe ECG app is not intended for use by people under 22 years old.
ECG App Instructins fr Use Apple Inc. One Apple Park Way Cupertin, CA 95014 www.apple.cm INDICATIONS FOR USE The ECG app is a sftware-nly mbile medical applicatin intended fr use with the Apple Watch t
More informationDivision of Nuclear Medicine Procedure / Protocol
Divisin f Nuclear Medicine Prcedure / Prtcl GASTRIC EMPTYING CPT CODE: 78264 UPDATED: FEBRUARY 2013 Indicatins: Patient Prep: Scheduling: This examinatin: Is indicated in patients with diabetes and thse
More informationDATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS
DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this
More informationCnsideratin fr Optimizatin: Optimizatin is a prgram transfrmatin technique, which tries t imprve the cde by making it cnsume fewer resurces (i.e. CPU, Memry) and deliver high speed. In ptimizatin, high-level
More informationIntended Use KontrolFlex Endodontic Rotary Files fit into a dental handpiece allowing the user to perform root canal debridement.
KntrlFlex Enddntic Rtary Files KntrlFlex Enddntic Rtary Files are available Nn-Sterile with varius ISO tip sizes and wrking lengths. The devices are intended t be cleaned and sterilized using steam sterilizatin
More informationABIOpure TM Total RNA (version 2.0)
ABIOpure TM Ttal RNA (versin 2.0) Bld Extractin Handbk Cat N: M541RP50-B FOR RESEARCH USE ONLY Table f Cntents Cntents Page Kit Cmpnents 3 Precautins 3 Stability & Strage 4 General Descriptin 4 Limitatins
More informationRate Lock Policy. Contents
Rate Lck Plicy Cntents Rate Lcks... 2 Rate Lck Cnfirmatin... 2 Lck Term... 2 Pre-Lck... 2 Maximum Qualified Rate... 3 Extensins... 3 Cst t Extend... 3 Relcks... 4 Re-Negtiatin r Flat Dwn Plicy... 4 Prgram
More informationCross-Platform Comparison of IL-6 Immunoassays. Maribeth Raines, PhD. Vice President of Laboratory Services. May 17, 2016 Biomarker World Congress
Crss-Platfrm Cmparisn f IL-6 Immunassays Maribeth Raines, PhD Vice President f Labratry Services May 17, 2016 Bimarker Wrld Cngress 2016 Bimarker Wrld Cngress 2 Cmpany Overview Funded in 1989 as spin ff
More informationCancer Immunology, Immunotherapy (submitted in 2014) Christian Krug et al.
Cancer Immunlgy, Immuntherapy (submitted in 2014) Christian Krug et al. PBMC day 0 d 0 n anti-cd3 side scatter d 0 with anti-cd3 frward scatter PBMC day 10 d 10 n anti-cd3 side scatter d 10 with anti-cd3
More informationPROTOCOL. SOD2 Protein Quantity Microplate Assay Kit. MS746 Rev.0 DESCRIPTION INTRODUCTION
PROTOCOL SOD2 Prtein Quantity Micrplate Assay Kit 1850 Millrace Drive, Suite 3A Eugene, Oregn 97403 MS746 Rev.0 DESCRIPTION SOD2 Prtein Quantity Micrplate Assay Kit Sufficient materials are prvided fr
More informationEXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS
1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics
More informationRecommendations for Risk Management at Swine Exhibitions and for Show Pigs August 2012
Recmmendatins fr Risk Management at Swine Exhibitins and fr Shw Pigs August 2012 Backgrund: The Natinal Prk Bard facilitated in develping this dcument. These recmmendatins were develped by a wrking grup
More informationA foot x-ray series is required only if there is pain in the midfoot zone and any one of the following:
RADIOGRAPHY OF THE ANKLE AND FOOT (OTTAWA ANKLE RULES) Clinical Practice Guideline January 2007 This guideline has been adapted frm the Ottawa Ankle Rules develped by Dr. Ian Stiell et al. Dr. Stiell received
More informationThe Effects of the Electroejaculation Procedure on Sperm. Motility
Paraplegia 27 (1989) 45-49 0031-1758/89/0027-045$10.00 :C' 1989 Internatinal Medical Sciety f Paraplegia The Effects f the Electrejaculatin Prcedure n Sperm. Mtility T. Linsentneyer, MD,! C. Wiltnt, MD,t
More informationCSE 331, Spring 2000
YOUR NAME: SECTION NUMBER: CSE 331, Spring 2000 Class Exercise 15 Algrithm Design Techniques-Greedy Algrithms March 13, 2000 Fllwing are five f the cmmn types f algrithms. Fr many prblems it is quite likely
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationThe estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by
ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the
More informationFor Research Use Only Ver
INSTRUCTION MANUAL Quick-cfRNA Serum & Plasma Kit Catalg N. R1059 Highlights High-quality cell-free RNA is easily and rbustly purified frm up t 3 ml f plasma, serum, r ther bilgical fluids. Purified cell-free
More informationDevelopment of Automation in Semen Analysis
Develpment f Autmatin in Semen Analysis Matt Tmlinsn PhD Cnsultant Scientist in Reprductin Nttingham University Hspital University f Nttingham Msc Assisted Reprductin Scientific Directr Prcreative Diagnstics
More information2018 Medical Association Poster Symposium Guidelines
2018 Medical Assciatin Pster Sympsium Guidelines Overview The 3 rd Annual student-run Medical Assciatin f the State f Alabama Research Sympsium will take place n Friday and Saturday, April 13-14 at the
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationHow to become an AME Online
Hw t becme an AME Online 1. Check that yu meet the minimum technical requirements in rder t use the AME Online system: Operating System: Windws Vista (Service Pack 2) Windws 7 Windws 8, 8.1 Windws 10 Please
More informationBROCKTON AREA MULTI-SERVICES, INC. MEDICAL PROCEDURE GUIDE. Date(s) Reviewed/Revised:
Page 1 f 6 Subject: Range f Mtin Exercises Date Develped: 4/2010 PROTOCOL FOR: All trained staff PURPOSE: Range f Mtin (ROM) exercises are very imprtant if an individual has t stay in bed r in a wheelchair.
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationFinding the right 90 people in 90 days and what to do with them:
Finding the right 90 peple in 90 days and what t d with them: Wh can yu give the 3 packets (with instructins) t? Current Preferred Custmers nt currently n the Daily Essentials Packets. Friends and Family
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationHow to Get Set Up and Running with NDepend
Hw t Get Set Up and Running with NDepend Whether yu have purchased r dwnladed the trial f NDepend, we thank yu fr yur invlvement and interest in ur prduct. Here we have cmpiled a quick "Getting Started"
More information(Please text me on once you have submitted your request online and the cell number you used)
Dear Thank yu fr yur email, nted. Belw steps n hw t register as a service prvider. Please nte that nce yu have requested t becme a service prvider, yu need t sms/what s up me n 0826392585, in rder t activate
More informationVITAPRO. Detoxification properties of Apple pectin formulation, PROPECTIN. CENTRE D ETUDE ET DE VALORISATION DES ALGUES FINAL REPORT.
CENTRE D ETUDE & DE VALORISATION DES ALGUES 2400 Detxificatin prperties f Apple pectin frmulatin, PROPECTIN. VITAPRO FINAL REPORT PrPectin July 2015 CENTRE D ETUDE ET DE VALORISATION DES ALGUES PRESQU
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationDaily Balancing in Maestro
Daily Balancing in Maestr Successful Daily Balancing in Maestr is based n utilizing reprts that cntain key peratinal and financial infrmatin based n yur prperty s requirements Maestr has 3 Key Daily Reprts
More informationCognitive Processing for Interpreters. Humanities and Social Sciences Division. o Work Experience, General. o Open Entry/Exit
SECTION A - Curse Infrmatin 1. Curse ID: 2. Curse Title: 3. Divisin: 4. Department: SIGN 227 Cgnitive Prcessing fr Interpreters Humanities and Scial Sciences Divisin Sign Language Department 5. Subject:
More informationEURL-SRM - Analytical Observations Report
cncerning the fllwing EURL-SRM - Analytical Observatins Reprt Cmpund(s): Pymetrzine Cmmdities: Varius cmmdities f plant rigin Methd(s): QuEChERS, adjustment f ph Instrumentatin: LC-MS/MS Analysis f Pymetrzine
More information2017 SPERM QUALITY ANALYSIS MES CATALOGUE
2017 SPERM QUALITY ANALYSIS MES CATALOGUE [ 2 ] CONTENTS Page Section 4 7 Sperm quality analyzers 8 9 Digital systems for sperm analysis 15 19 Additional information [ 3 ] SPERM ANALYSIS SQA-Vision Sperm
More informationDIRECTED FORGETIING: SHORT-TERM MEMORY OR CONDITIONED RESPONSE? WENDY S. MILLER and HARVARD L. ARMUS The University of Toledo
The Psychlgical Recrd, 1999, 49, 211-220 DIRECTED FORGETIING: SHORT-TERM MEMORY OR CONDITIONED RESPONSE? WENDY S. MILLER and HARVARD L. ARMUS The University f Tled Previus researchers have interpreted
More informationInstructions for Use INTRON A (In-tron-aye) (Interferon alfa-2b, recombinant) Powder for Solution
Instructins fr Use INTRON A (In-trn-aye) (Interfern alfa-2b, recmbinant) Pwder fr Slutin Be sure that yu read, understand, and fllw these instructins befre injecting INTRON A. Yur healthcare prvider shuld
More informationInformationNOW Attendance
InfrmatinNOW Attendance Abut this Guide This Quick Reference Guide prvides an verview f the setup, entry and reprting f attendance in InfrmatinNOW. Users are advised t refer the apprpriate InfrmatinNOW
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationImaging tests allow the cancer care team to check for cancer and other problems inside the body.
IMAGING TESTS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between yu
More informationYear 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:
Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:
More informationREGISTERED REPORTS AUTHOR AND REVIEWER GUIDELINES
REGISTERED REPORTS AUTHOR AND REVIEWER GUIDELINES A Registered Reprt is a frm f empirical article ffered at Nature Human Behaviur in which the methds and prpsed analyses are pre-registered and reviewed
More informationPatterns of Cholesterol Distribution in the Participants of a Screening Project
Patterns f Chlesterl Distributin in the Participants f a Screening Prject Abdul Hamid Shaikh, S With guidelines similar t thse recmmended by the Natinal Chlesterl Educatin Prgram (NCEP), 3,3 individuals
More information2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE
2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizatins, Clinical Cascade Breakut Sessin TB/HIV EXERCISE Created by the ICPI TB/HIV Wrkstream Abut this Handut
More informationPercutaneous Nephrolithotomy (PCNL)
Percutaneus Nephrlithtmy (PCNL) What is a percutaneus nephrlithtmy? is the mst effective f the cmmnly perfrmed prcedures fr kidney stnes. It is the best prcedure fr large and cmplex stnes. T perfrm this
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationMeaningful Use Roadmap Stage Edition Eligible Hospitals
Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationCreating and Linking Charge Objects
Overview Charge bject screens are used t maintain cst accunting cdes that agencies use t break ut emplyee time based n wrk perfrmed and leave time while assigned t a specific prject(s). The charge bject
More informationInitial Postoperative Knee Care Patella or Quadriceps Tendon Repairs: - Videos are available on Dr. Witty s website: drjeffreywitty.
Initial Pstperative Knee Care Patella r Quadriceps Tendn Repairs: - Vides are available n Dr. Witty s website: drjeffreywitty.cm Imprtant Phne Numbers: - Please see the cntact infrmatin abve fr imprtant
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationExtended G/L Segment Codes
Extended G/L Segment Cdes Cpy Segment Cdes t ther Sage 300 cmpanies Extended G/L Segment Cdes Extended G/L Segment Cdes is an enhanced replacement fr the Sage G/L Segment Cdes screen. It lets yu cpy segment
More informationDirectory of Laboratory Services
Directry f Labratry Services Interpace Diagnstics Crpratin www.interpacediagnstics.cm TEL: 800.495.9885 CO-SOP-1007 Directry f Labratry Services Table f Cntents List f Testing Services... 3 Acceptable
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationPhysical Fitness for the Physically Limited. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses
SECTION A - Curse Infrmatin 1. Curse ID: 2. Curse Title: 3. Divisin: 4. Department: 5. Subject: 6. Shrt Curse Title: 7. Effective Term:: KINL 2 Physical Fitness fr the Physically Limited Kinesilgy & Athletics
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationDental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.
Dental Benefits Under the TeamstersCare Plan, yu and yur eligible dependents have three basic ptins when yu need dental care. Optin #1: TeamstersCare Dentists. Yu can use ur in-huse Charlestwn, Chelmsfrd,
More informationReliability and Validity Plan 2017
Reliability and Validity Plan 2017 Frm CAEP The principles fr measures used in the CAEP accreditatin prcess include: (a) validity and reliability, (b) relevance, (c) verifiability, (d) representativeness,
More informationRelationship Between Fertility and the Nonprotein Sulfhydryl Concentration of Seminal Fluid in the Thoroughbred Stallion
Relatinship Between Fertility and the Nnprtein Sulfhydryl Cncentratin f Seminal Fluid in the Thrughbred Stallin Frederick M. Haag, D.V.M., * and N. T. Werthessen, Ph.D. IN AN EARLIER REPORT! it was shwn
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationPain relief after surgery
Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read
More informationWU-Minn HCP 900 Subjects Data Release: Reference Manual
WU-Minn HCP 900 Subjects Data Release: Reference Manual Appendix VI Task fmri and tmeg E-Prime Key Variables 8 December 2015 900 Subjects Reference Manual Appendix VI WU-Minn Cnsrtium f the NIH Human Cnnectme
More informationNATIONAL SENIOR CERTIFICATE GRADE 12
NATIONAL SENIOR CERTIFICATE GRADE 12 INFORMATION TECHNOLOGY P1 FEBRUARY/MARCH 2015 MARKS: 150 TIME: 3 hurs This questin paper cnsists f 19 pages. Infrmatin Technlgy/P1 2 DBE/Feb. Mar. 2015 INSTRUCTIONS
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationRefining Blood Collection Techniques to Improve Animal Welfare and Sample Quality
Refining Bld Cllectin Techniques t Imprve Animal Welfare and Sample Quality Amy Allaire RLATG 1, Jennifer Jhnsn 2, Kimberly Maratea DVM PhD 2, Steven Bulé CMAR RLATG 1, Sara Savage DVM DACLAM 1 1 Dispsitin,
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationRadiographic Procedures I Laboratory. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses
SECTION A - Curse Infrmatin 1. Curse ID: 2. Curse Title: 3. Divisin: 4. Department: 5. Subject: 6. Shrt Curse Title: 7. Effective Term:: RAD 61C Radigraphic Prcedures I Labratry Technlgy and Health Divisin
More informationPaulo C. Serafini, M.D.t+ Douglas Hauser, B.S. Dean Moyer, M.D. Richard P. Marrs, M.D.tll
FERTLTY AND STERLTY Cpyright" 1986 The American Fertility Sciety Vl. 46, N.4, Octber 1986 Printed in U.SA. Crypreservatin f human spermatza: crrelatins f ultrastructural sperm head cnfiguratin with sperm
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationEASTERN ARIZONA COLLEGE Criminal Investigation
EASTERN ARIZONA COLLEGE Criminal Investigatin Curse Design 2017-2018 Curse Infrmatin Divisin Scial Sciences Curse Number AJS 103 Title Criminal Investigatin Credits 3 Develped by Kris Matthews Lecture/Lab
More informationRequirement for all Industrial Stairs
Requirement fr all Industrial Stairs (This is the same as Table D-1 in OSHA Standard 29 CFR 1910.24(e)) Angle t Hrizn Rise Height (in inches) Tread Width (in inches) 30 6 ½ 11 32 6 ¾ 10 ¾ 33 7 10 ½ 35
More informationIntroduction. Lesson developed by: Heather Medema-Johnson, M.S, ATC, CSCS
Updated DATE BSL PRO Lessn H35: Range f Mtin/Sit and Reach Lessn develped by: Heather Medema-Jhnsn, M.S, ATC, CSCS Intrductin A well-runded physical activity prgram is an integral part f a strng, verall
More informationo hold ankle (first uninvolved, then involved) o hold 4 seconds
Prtcl fr Cx Technique Hands-On Prtins f Curses step by step instructins fr treating patients with Cx Distractin Decmpressin Adjustment & Manipulatin Prtcl I and II Instructins Lumbar Spine prepared by
More informationEMC believes the information in this publication is accurate as of its publication date. The information is subject to change without notice.
EMC DATA PROTECTION ADVISOR (DPA) MIGRATION TECH NOTE With SQL as external database fr t 5.5.1 and later DPA versin 5.x releases t 6.0 SP1 and later ABSTRACT This Tech Nte prvides the steps t migrate frm
More informationM.J. Guthriel, D.G. Wagner2
EFFECT OF SUPPLEMENTAL PROTEIN OR GRAIN ON INTAKE AND UTILIZATION OF MEDIUM QUALITY PRAIRIE HAY BY STEERS M.J. Guthriel, D.G. Wagner2 and D.C. Weakley3 Stry in Brief Sixteen 1,053 lb tw-year-ld Herefrd
More informationBefore Your Visit: Mohs Skin Cancer Surgery
Befre Yur Visit: Mhs Skin Cancer Surgery Yur Kaiser Permanente Care Instructins Skin Cancer Infrmatin What is skin cancer? Skin cancers are tumrs, r malignancies, f the skin. Skin cancer is assciated with
More informationLTCH QUALITY REPORTING PROGRAM
4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04
More informationAccounting Assessment Report
Accunting 2014-2015 Assessment Reprt 1. Please give a brief verview f the assessment data yu cllected this year. This can be in any frm yu feel is apprpriate, such as a table, a shrt narrative f results,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationWork Experience - Athletic Training. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses
SECTION A - Curse Infrmatin 1. Curse ID: 2. Curse Title: 3. Divisin: 4. Department: 5. Subject: 6. Shrt Curse Title: 7. Effective Term:: KIN 92 Wrk Experience - Athletic Training Kinesilgy & Athletics
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationBasic Thyroid Examination
Basic Thyrid Examinatin WIPE Wash hands Intrduce yurself Permissin Psitin (Patient sat in frnt f yu upright) Expsure (Neck expsed) Identify Patient (cnfirm the fllwing details befre starting) Name Age
More informationFUNCTIONAL MOVEMENT SYSTEMS SCREEN FINDINGS REPORT
FUNCTIONA MOVEMENT SYSTEMS SCEEN FINDINGS EPOT Screening Date: Client: FMS Certified Member: FMS Scre: 09/0/1 04:15 PM Glenn D'Avanz Elizabeth Carus 17 Descriptin: FMS screen fr Glenn D'Avanz FUNCTIONA
More information